Merck Acquires Afferent Pharmaceuticals

Represented Merck in its acquisition of Afferent Pharmaceuticals for $500 million cash up front plus additional consideration of up to $750 million.

Merck is a pharmaceutical company that operates in three main segments: life sciences, performance materials, and healthcare. Afferent Pharmaceuticals is a developer of drugs for the treatment of neurogenic disorders.*